These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22186077)

  • 41. Heptavalent pneumococcal conjugate vaccine (PCV7): French survey of serious adverse reactions.
    Autret-Leca E; Grimaldi-Bensouda L; Daubin C; Poggi P; Collignon AE; Jonville-Béra AP
    Therapie; 2011; 66(1):81-6. PubMed ID: 21466782
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Treatment recommendations for type 2 diabetes. Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS)].
    Diabetes Metab; 1999 Dec; 25 Suppl 6():1-79. PubMed ID: 10697746
    [No Abstract]   [Full Text] [Related]  

  • 43. Updates for the antibiotic treatment of legionellosis in adults. Agence française de sécurité sanitaire des produits de santé.
    Dumarcet N;
    Med Mal Infect; 2012 Sep; 42(9):393-403, 403-13. PubMed ID: 22921502
    [No Abstract]   [Full Text] [Related]  

  • 44. [Reform Act on safety of drug and health products in France: announcement effect, strengthening or upheaval?].
    Maillols-Perroy AC; Tillet Y
    Therapie; 2012; 67(1):1-10. PubMed ID: 22487499
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Automatic generation of MedDRA terms groupings using an ontology.
    Declerck G; Bousquet C; Jaulent MC
    Stud Health Technol Inform; 2012; 180():73-7. PubMed ID: 22874155
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety aspects of antiepileptic drugs--focus on pharmacovigilance.
    Landmark CJ; Johannessen SI
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21(1):11-20. PubMed ID: 22069221
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Overview of adverse reactions to nefopam: an analysis of the French Pharmacovigilance database.
    Durrieu G; Olivier P; Bagheri H; Montastruc JL;
    Fundam Clin Pharmacol; 2007 Oct; 21(5):555-8. PubMed ID: 17868209
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor?
    Trifirò G; Pariente A; Coloma PM; Kors JA; Polimeni G; Miremont-Salamé G; Catania MA; Salvo F; David A; Moore N; Caputi AP; Sturkenboom M; Molokhia M; Hippisley-Cox J; Acedo CD; van der Lei J; Fourrier-Reglat A;
    Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1176-84. PubMed ID: 19757412
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Using a capture-recapture method to assess the frequency of adverse drug reactions in a French university hospital.
    Lugardon S; Desboeuf K; Fernet P; Montastruc JL; Lapeyre-Mestre M
    Br J Clin Pharmacol; 2006 Aug; 62(2):225-31. PubMed ID: 16842398
    [TBL] [Abstract][Full Text] [Related]  

  • 50. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
    Fleuranceau-Morel P
    Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
    [TBL] [Abstract][Full Text] [Related]  

  • 51. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Monitoring the safety of drugs and COVID-19 vaccines by the French Pharmacovigilance Centers during the pandemic: a win-win bet with Health Authorities!].
    Jonville-Bera AP; Gautier S; Micallef J; Massy N; Atzenhoffer M; Drici MD; Grandvuillemin A;
    Therapie; 2023; 78(5):477-488. PubMed ID: 36890032
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A quantitative approach of using genetic algorithm in designing a probability scoring system of an adverse drug reaction assessment system.
    Koh Y; Yap CW; Li SC
    Int J Med Inform; 2008 Jun; 77(6):421-30. PubMed ID: 17921048
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Child overdose: the value of the French pharmacovigilance causality assessment method.
    Rajab M; Lagier G; Eftekhari P; Ginisty S; Bazire A; Garnier R
    Therapie; 2004; 59(6):603-6. PubMed ID: 15789822
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Analysis of generic drug supply in France].
    Taboulet F; Haramburu F; Latry P
    Rev Epidemiol Sante Publique; 2003 Sep; 51(4):415-25. PubMed ID: 13679734
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epidemiological surveillance of infectious diseases in France.
    Dufour B; La Vieille S
    Vet Res; 2000; 31(2):169-85. PubMed ID: 10779198
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adverse drug reactions: moving from chance to science.
    Haller C; James LP
    Clin Pharmacol Ther; 2011 Jun; 89(6):761-4. PubMed ID: 21593747
    [No Abstract]   [Full Text] [Related]  

  • 58. [Cutaneous adverse drug reactions: enhanced imputation score by skin testing].
    Choquet-Kastylevsky G; Vial T; Santolaria N; Nageotte A; Faure M; Claudy A; Descotes J
    Ann Dermatol Venereol; 2001 Apr; 128(4):507-11. PubMed ID: 11395648
    [TBL] [Abstract][Full Text] [Related]  

  • 59. French Pharmacovigilance Public System and COVID-19 Pandemic.
    Grandvuillemin A; Drici MD; Jonville-Bera AP; Micallef J; Montastruc JL;
    Drug Saf; 2021 Apr; 44(4):405-408. PubMed ID: 33372244
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacovigilance in New Zealand: the role of the New Zealand Pharmacovigilance Centre in facilitating safer medicines use.
    Kunac DL; Harrison-Woolrych M; Tatley MV
    N Z Med J; 2008 Oct; 121(1283):76-89. PubMed ID: 18841188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.